">

Based on improving new product visibility, benefits from restructuring initiatives, and near-term volume boost from Medicare Part D supports our Attractive rating for the U.S. pharmaceutical sector.

Facebooktwitterredditpinterestlinkedintumblr

Related Quotes

popup close button